HUGE! Employers Can Now Offer Zepbound Through New Lilly Program!
- Dave Knapp
- Mar 10
- 7 min read
Originally posted on obesity.news on March 5th, 2026
Something very exciting was announced today that may not look extremely dramatic on the surface but could end up reshaping how millions of Americans access obesity treatment. Affordably.
Eli Lilly announced the launch of Lilly Employer Connect, a platform designed to help employers offer obesity treatment coverage for their employees, including Zepbound.
Early headlines have focused on a single number.
$449 for Zepbound.
But it’s important to understand what that number actually represents.
The $449 price is not what employees will necessarily pay. Patients could already opt for the cash pay price through Lilly direct at that price. No, this is the program’s starting price to pharmacies inside Lilly’s employer platform, essentially functioning as a wholesale or list style price within the system. From that $449 starting number, employers choose how much of that cost they subsidize.
Depending on the program design, that means the actual out of pocket cost for employees could be significantly lower than $449.
That flexibility is the entire reason Lilly structured the platform this way. Instead of forcing companies to adopt a one size fits all insurance benefit, Employer Connect allows employers to design coverage that fits their workforce and their healthcare budgets.
ON THE PEN is a reader-supported publication.
To receive new posts and support my work,
consider becoming a free or paid subscriber.
In other words, the $449 number is the ceiling on the drug cost, not the final patient price.
And when you zoom out, this program starts to look like something much bigger. It looks like an attempt to fix a structural problem in the American healthcare system that millions of obesity patients are currently living through.
And if you listened to this past week’s podcast, the issue Lilly is trying to solve should sound very familiar.
The problem Lilly is trying to solve
More than 100 million Americans live with obesity, yet coverage for anti obesity medications remains wildly inconsistent.Roughly half of commercially insured employees still lack coverage for obesity drugs, according to Lilly.
Employers that want to cover them often run into a complicated barrier. The traditional path requires renegotiating benefit structures with insurers and PBMs, adjusting formularies, and absorbing the risk of unpredictable drug spending. For many, plans that include obesity coverage are not offered at all.
For medications that can cost a plan over $1,000 monthly, many employers simply choose not to offer coverage.
That leaves patients in a strange place.
Because the system they are paying into often refuses to cover the medication their doctor prescribes.
The reality patients are living in right now
At the start of this past week’s episode of the On The Pen podcast, I described the strange situation many GLP-1 patients are experiencing.
People are paying enormous premiums into the healthcare system. They go to their doctor, they get prescribed a GLP-1 medication, and then the insurance company denies coverage.
As I explained on the show:
“You might be paying upwards of $30,000 a year for your family plan. Meanwhile, you go get prescribed the GLP-1 and your insurance says no. So you go to the pharmacy and it’s $500 and it doesn’t even count toward your deductible.”
That contradiction is exhausting for patients.
Patients living with obesity are paying exorbitantly into a system that ultimately forces them to purchase treatment outside of it. And that dynamic has created something unusual. Two healthcare systems operating at the same time.
The two systems that now exist
On one side you have the traditional insurance ecosystem.
That world is dominated by PBMs, rebates, formularies, and coverage exclusions.
On the other side you have a rapidly growing direct consumer GLP-1 economy where companies are offering transparent pricing and telehealth prescribing outside the insurance system entirely.
During this past week’s podcast, we talked about several examples of that shift.
Walgreens launching a virtual weight management clinic.
Amazon offering GLP-1 telehealth access.
Lilly building LillyDirect.
As I explained during the episode, retail and technology companies are creating an entirely new pathway because traditional insurance coverage has failed to keep up. Employer Connect appears to be Lilly’s attempt to bridge those two worlds.
“Retail and tech are building this sort of parallel lane to our healthcare system… because more than half of large employers still do not cover GLP-1 medications for obesity.”
What Lilly Employer Connect actually does
Instead of forcing employers to modify their entire health insurance plan, Employer Connect allows companies to add an obesity treatment benefit alongside their existing coverage.
Employers connect with a network of more than 15 independent program administrators.
Those administrators include organizations like:
Teladoc
GoodRx
Calibrate Health
Form Health
Sesame
Transcarent
9amHealth
These organizations can provide everything from basic benefits administration to comprehensive obesity care programs that include physician oversight, behavior change support, and medication access.
Employers can choose the structure that fits their workforce and their budget.
That flexibility is the entire point.
The $449 price that everyone will notice
One of the most interesting details in the announcement is the $449 price Lilly will charge pharmacies for Zepbound through the program.
This is not the price patients pay.
It is the acquisition price for pharmacies participating in the network.
From there, the final cost depends on several variables.
The employer’s cost sharing designThe program administrator managing the benefitDispensing and service feesThe pharmacy selected
The medication itself will be distributed using the Zepbound KwikPen, a single patient device that delivers four weekly injections.
If employers subsidize part of the cost, employee copays could drop dramatically compared with traditional cash pay pricing.
A new distribution model
Another important piece of this program is the pharmacy network.
Dispensing will occur through partners including HealthDyne and CenterWell.
This gives Lilly more control over distribution and pricing transparency compared with the traditional PBM driven supply chain.
It also mirrors the broader strategy the company has been building with LillyDirect.
Instead of relying entirely on the traditional pharmaceutical distribution ecosystem, Lilly is developing alternative access pathways.
Employer Connect appears to be the employer focused version of that strategy.
Why employers might actually adopt this
Employers have historically been hesitant to cover GLP-1 medications for one simple reason.
Financial unpredictability.
If a large portion of employees begin therapy, drug spending can spike dramatically.
Employer Connect attempts to solve that problem in three ways.
First, the drug price is fixed at the pharmacy acquisition level.
Second, the benefit exists outside the employer’s traditional insurance plan.
Third, employers can control eligibility requirements and cost sharing structures.
According to Lilly executive Kevin Hern, the goal is to give employers more flexibility in how they
provide access to obesity treatment.
“By enabling coverage outside traditional benefit designs, we lower barriers to treatment and give employers greater control over how they support employee access to obesity care.” -Kevin Hern, Lilly
The bigger structural shift happening right now
One of the central themes of this past week’s podcast was that the entire healthcare system is shifting around GLP-1 medications.
We talked about several forces reshaping the landscape at the same time.
Congress restructuring PBM incentives.
Regulators potentially tightening compounding through the demonstrably difficult to compound list.
State legislatures considering additional restrictions on compound pharmacies.
Retail companies launching GLP-1 prescribing platforms.
Artificial intelligence accelerating drug discovery.
When you step back, it becomes clear that the entire healthcare system is reorganizing itself.
As I said on the episode:
“The healthcare system as we know it is reorganizing itself in real time.”
Employer Connect fits directly into that transformation.
What this means for patients
If employers adopt this platform at scale, millions of employees who currently lack obesity medication coverage could gain access.
But it is important to be realistic about what this program does and does not solve.
It primarily benefits people who receive health insurance through employers that choose to participate.
It does not immediately address access for:
Medicare patients (Part D coverage coming in July)Uninsured individuals (cash pay through Lilly Direct)Workers at companies that decline the program (cash pay through Lilly Direct)
So while this may expand access for many people, others will still remain in the cash pay lane, one that still arguably prices out too many.
How employees can bring this to their employer
If you read this announcement and thought, I wish my employer offered this, you are not alone.
Programs like Lilly Employer Connect are employer driven, which means employees can play a
role in getting them adopted.
Most companies make benefits decisions through their Human Resources or Benefits team, often with the help of outside benefits consultants.
That means awareness matters.
If you want your employer to consider a program like this, start with your HR or benefits department. Share the announcement and explain why access to obesity treatment matters to you and your coworkers. Employers are often unaware of how many employees are struggling to access care until someone speaks up.
It can also help to frame the conversation around health outcomes and productivity. Obesity treatment is increasingly linked to reduced risk of heart disease, diabetes, sleep apnea, and other costly conditions. Employers respond when they see that treating obesity can improve employee wellbeing and potentially reduce long term healthcare costs.
Employers who want more information can also reach Lilly directly.
The company has created a dedicated contact for the program:
This email connects employers and benefits consultants with Lilly’s Employer Connect team and the administrators participating in the platform.
Change inside organizations often begins with one employee raising the issue. For decades obesity treatment has been treated differently from other chronic diseases in employer health plans.
Programs like this are beginning to shift that mindset, but employees can help start the conversation.
The bottom line
Employer Connect is not just another benefits program.
It is a signal.
It shows that pharmaceutical companies understand something patients have been saying for years.
The traditional healthcare system was never designed to handle modern obesity treatment.
So new pathways are beginning to emerge.
Direct consumer models.
Retail clinics.
Employer sponsored access programs.
Each of these is trying to solve the same problem from a different direction.
Patients have been living inside this broken system long before policymakers and industry fully acknowledged it.
Now the industry is starting to build solutions around the reality patients have been describing.
And that transformation is happening faster than most people realize.
This is a good day for patients.
Stay tuned to OnThePen.com for more updates and in-depth analysis on the latest developments in weight loss and diabetes treatments. Sharing this article is a powerful form of advocacy that brings us closer to our goal of educating the masses and reducing the stigma of obesity. If you found this article insightful, please share it within your networks, especially in Facebook groups and Reddit forums dedicated to GLP-1 medications and diabetes management. Together, we can make a difference.
This was a really interesting read! I didn’t know much about this topic before, but the way you explained it made everything much clearer and easier to understand. It reminded me of how useful structured and persuasive methods can be, like the ones you find in Help with Assignment. Even though that’s usually about writing, the idea of organizing ideas clearly and presenting them in a way that keeps the reader engaged really applies here too. I sometimes struggle to grasp new topics quickly, but posts like this make it much easier. I liked how it was simple to follow without skipping important details. Thanks for sharing I feel like I learned something new today and will definitely keep these…